Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
02:49pm, Tuesday, 05'th May 2026
ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
07:30am, Monday, 04'th May 2026
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equiv
Agree Realty: Bigger Investments, Stronger Growth Amid Uncertainty Puts Them In A Different League
08:30am, Friday, 01'st May 2026
Agree Realty (ADC) continues to outperform peers, demonstrating resilient growth despite higher interest rates and economic uncertainty. ADC reported robust Q1 results: 8% AFFO and core FFO growth, $4
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05am, Friday, 01'st May 2026
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
04:15pm, Wednesday, 29'th Apr 2026
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
07:30am, Monday, 27'th Apr 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t
Agree Realty: Reliable Dividend Income To Weather The Macro Storm
02:31am, Saturday, 25'th Apr 2026
Agree Realty remains a Buy, supported by strong Q1 results, a robust investment pipeline, and prudent management amid macro uncertainty. ADC posted 7.9% AFFO per share growth in Q1, reaffirmed 2026 gu
Dividend Champion, Contender, And Challenger Highlights: Week Of April 26
08:45pm, Friday, 24'th Apr 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
This Portfolio Pays Me Every Month (No Work Needed)
11:34am, Friday, 24'th Apr 2026
The 10-year Treasury yield sits at 4.26% and the Fed funds rate has been held at 3.75% for more than four months.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Thursday, 23'rd Apr 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Agree Realty Corporation (ADC) Q1 2026 Earnings Call Transcript
03:50pm, Wednesday, 22'nd Apr 2026
Agree Realty Corporation (ADC) Q1 2026 Earnings Call Transcript
Agree Realty (ADC) Surpasses Q1 FFO and Revenue Estimates
06:36pm, Tuesday, 21'st Apr 2026
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.14 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to FFO of $1.06 per share a year ago.
Agree Realty Corporation Reports First Quarter 2026 Results
04:05pm, Tuesday, 21'st Apr 2026
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended March 31, 2026. All per share amounts included herein are on a
Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
08:15pm, Sunday, 19'th Apr 2026
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for onc
